Bifidobacterium pseudolongum reduces triglycerides by modulating gut microbiota in mice fed high-fat food

Obesity has become a growing concern around the world. The purpose of this study was to investigate the potential benefit of Bifidobacterium pseudolongum (B. pseudolongum) on obesity, gut microbiota, and its physiological mechanism. The obese mice model was established with a high-fat diet (HFD), and the treatment were used the strain B. pseudolongum. We investigated the changes in fat content, plasma metabolites and gut microbiota on obese mice and B. pseudolongum treated obese mice. We found that B. pseudolongum treatment significantly decreased the body mass (about 12 %), plasma triglycerides (about 12.4 %), gross energy intake (about 12.8 %), and visceral fat (about 26.5 %) in obese mice. Further, High-throughput pyrosequencing of the 16S rRNA demonstrated that B. pseudolongum treatment markedly recovered the gut microbiota dysbiosis in obese mice, including the diversity of microbiota and the ratio of Firmicutes to Bacteroidetes. B. pseudolongum treatment increased the abundance of the bacterial genus Butyricimonas and Bifidobacterium. Therefore, B. pseudolongum may have therapeutic potential for the treatment of diet-induced obesity (DIO). B. pseudolongum treatment could change host gut microbiota and provide benefits to host digestive processes that mitigate metabolic diseases.